Cerenome

Connecting precision diagnostics, targeted therapeutics, & patient data into an integrated CNS oncology platform.

(previously Plus Therapeutics)

$CNSY

[Cerenome @cerenome]

$PSTV announces that its corporate rebrand to Cerenome will be completed as scheduled.

Effective on Monday, August 3, 2026, $PSTV's name will become Cerenome, Inc. and its common stock will begin trading on the @Nasdaq Capital Market under the new ticker symbol CNSY.

The new name reflects the Company's de facto evolution from a therapeutics-focused organization into an integrated CNS oncology company. Cerenome integrates precision diagnostics, targeted
therapeutics, and AI to improve how CNS cancers are detected, treated, and understood.

Full press release here: https://t.co/ZrknVc9T2S

@NasdaqExchange @CNSideDx

[Cerenome @cerenome]

On August 3, $PSTV will officially become Cerenome (@Nasdaq: CNSY).

As our President and CEO Dr. Marc Hedrick discusses in the video below, the foundation of the Cerenome platform is designed to approach central nervous system (CNS) cancer as a solvable system by:

- Advancing our lead drug REYOBIQ™ through late-stage development
- Bringing to market a complete portfolio of cerebrospinal fluid (CSF) diagnostic solutions under the @CNSideDx brand
- Using native AI and novel data insights to drive strategy, operations, pipeline development, and partnering

Read our mid-year business update and shareholder letter to learn more as we prepare for this exciting transition:

Business Update: https://t.co/PqIaeFJtG3

Shareholder Letter: https://t.co/YZ5NJ4Bxfg

[Cerenome @cerenome]

$PSTV announces scientific presentations and sponsored symposium at the 2026 @NeuroOnc / @ASCO CNS Metastases Conference that will highlight research across its REYOBIQ™ clinical development program and @CNSideDx's cerebrospinal fluid diagnostic platform.

$PSTV and CNSide will also host a sponsored symposium that will bring together leading key opinion leaders to discuss the evolving management of leptomeningeal metastases.

Learn more here: https://t.co/bkyIXOQnMX

Pre-register or request a copy of the symposium recording here: https://t.co/duQjCerhlc

[Cerenome @cerenome]

Coming August 3rd: Our new identity from $PSTV to Cerenome reflects a natural evolution. We are more than a therapeutics company - we are an integrated CNS Oncology platform advancing diagnostics, therapeutics, and clinical data, designed to transform CNS cancer care.

Our Vision for the future: CNS cancers have historically been considered some of the most difficult challenges in medicine. But we 𝐓𝐡𝐢𝐧𝐤 𝐢𝐭 𝐬𝐨𝐥𝐯𝐚𝐛𝐥𝐞.

Learn more: https://t.co/SVETsBaPV6

Letter from the CEO regarding the rebrand: https://t.co/ePBmr5coZJ

Effective August 3, 2026, Plus Therapeutics will change its corporate name to Cerenome, Inc. and begin trading under the Nasdaq ticker symbol CNSY. Until that date, the Company will continue to operate as Plus Therapeutics and trade under the ticker symbol $PSTV.

[Cerenome @cerenome]

$PSTV has signed a regional agreement with @medmutual effective July 1, 2026, covering ~ 1.2 million people throughout Ohio and Kentucky.

This brings the @CNSideDx CSF TCE assay total contracted coverage to approximately 127 million people.

Read more: https://t.co/SlmQemwhno

[Cerenome @cerenome]

$PSTV announces a collaboration to integrate @GenomicTesting Cooperative’s next-generation sequencing (NGS) technology into the @CNSideDx cerebrospinal fluid (CSF) assay platform.

The collaboration advances $PSTV's three-pillar CNS oncology strategy:
- Targeted radiotherapeutics led by REYOBIQ™ (rhenium Re186 obisbemeda)
- Precision diagnostics anchored by the CNSide CSF platform
- AI-enabled data analytics through the Company’s strategic partnership with Ephemeral Technologies

Full press release here: https://t.co/1KAhPBhh2I

[Cerenome @cerenome]

Today is Glioblastoma Awareness Day, an annual moment to raise awareness for glioblastoma patients, their families and caregivers, and the incredible advocacy organizations driving crucial awareness and research forward every day of the year.

Learn more about our brain cancer clinical trials: https://t.co/UHhiyylk8z

@NBTStweets @theABTA #GBMDay

[Cerenome @cerenome]

$PSTV highlights the recent update to the @NCCN Clinical Practice Guidelines in Oncology for CNS Cancers, including guidance relevant to leptomeningeal metastases, a serious and often underdiagnosed complication of advanced cancer.

Read more: https://t.co/WbAheBoKTW

@CNSideDx

[Cerenome @cerenome]

$PSTV CEO & President, Dr. Marc Hedrick, penned a letter to shareholders outlining the significant milestone of our company's upcoming brand evolution to Cerenome coming on August 3rd.

Read the full letter to learn more about our vision for the future of CNS oncology: https://t.co/vLD4icVlEi

[Cerenome @cerenome]

$PSTV is evolving its business and is rebranding to Cerenome starting August 3rd to reflect this ongoing expansion. As part of the change, $PSTV is now also delving more deeply into AI.

Learn more about our ongoing company evolution: https://t.co/yNwxttXsne

[Cerenome @cerenome]

Along with the excitement around the $PSTV rebrand to Cerenome and ticker change CNSY, our latest press release included several significant updates

Read more about our latest key milestones and positive @CNSideDx commercial progress: https://t.co/pOA5gr0yjR

[Cerenome @cerenome]

$PSTV announces it is changing its company name from Plus Therapeutics to Cerenome and @Nasdaq ticker to CNSY, effective August 3, 2026.

$PSTV will host a business update conference call and webcast today at 8:30 a.m. Eastern time to discuss the rebranding, progress to milestones and provide additional detail on the Company’s progress for @CNSideDx, REYOBIQ™, and its AI strategy.

Read more and join the call here: https://t.co/PqIaeFK1vB

@NasdaqExchange

[Cerenome @cerenome]

Today we’re featuring $PSTV's VP of Development & Technical Operations, Daniel Ortega!

Daniel leads our end-to-end drug development across the company’s radiotherapeutic portfolio, including: GMP manufacturing, clinical supply chain management, and CMC oversight.